Kleinschek Melanie A, Boniface Katia, Sadekova Svetlana, Grein Jeff, Murphy Erin E, Turner Scott P, Raskin Lisa, Desai Bela, Faubion William A, de Waal Malefyt Rene, Pierce Robert H, McClanahan Terrill, Kastelein Robert A
Department of Immunology, Schering-Plough Biopharma, Palo Alto, CA 94304, USA.
J Exp Med. 2009 Mar 16;206(3):525-34. doi: 10.1084/jem.20081712. Epub 2009 Mar 9.
The C-type lectin-like receptor CD161, which has recently been described to promote T cell expansion, is expressed on a discrete subset of human CD4 T cells. The function of such cells, however, has remained elusive. We now demonstrate that CD161(+) CD4 T cells comprise a circulating and gut-resident T helper 17 (Th17) cell population. During Crohn's disease (CD), these CD161(+) cells display an activated Th17 phenotype, as indicated by increased expression of interleukin (IL)-17, IL-22, and IL-23 receptor. CD161(+) CD4 T cells from CD patients readily produce IL-17 and interferon gamma upon stimulation with IL-23, whereas, in healthy subjects, priming by additional inflammatory stimuli such as IL-1beta was required to enable IL-23-induced cytokine release. Circulating CD161(+) Th17 cells are imprinted for gut homing, as indicated by high levels of CC chemokine receptor 6 and integrin beta7 expression. Supporting their colitogenic phenotype, CD161(+) Th17 cells were found in increased numbers in the inflammatory infiltrate of CD lesions and induced expression of inflammatory mediators by intestinal cells. Our data identify CD161(+) CD4 T cells as a resting Th17 pool that can be activated by IL-23 and mediate destructive tissue inflammation.
J Immunol. 2014-8-29
Proc Natl Acad Sci U S A. 2010-8-2
Int Arch Allergy Immunol. 2012-12-15
Curr Opin HIV AIDS. 2010-3
Front Immunol. 2025-8-14
Exp Mol Med. 2025-9-1
Antioxidants (Basel). 2025-6-13
Cell Commun Signal. 2024-12-18
Proc Natl Acad Sci U S A. 2024-11-19
Immunol Rev. 2008-6
Blood. 2008-8-15
Nat Rev Immunol. 2008-6
Immunity. 2008-4